Compare TTMI & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TTMI | HRMY |
|---|---|---|
| Founded | 1978 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0B | 2.0B |
| IPO Year | 2000 | 2020 |
| Metric | TTMI | HRMY |
|---|---|---|
| Price | $67.07 | $37.72 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 9 |
| Target Price | ★ $73.25 | $51.33 |
| AVG Volume (30 Days) | ★ 2.1M | 772.8K |
| Earning Date | 02-04-2026 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 90.88 | 50.44 |
| EPS | 1.26 | ★ 3.17 |
| Revenue | ★ $2,782,990,000.00 | $825,944,000.00 |
| Revenue This Year | $20.48 | $23.11 |
| Revenue Next Year | $9.21 | $16.15 |
| P/E Ratio | $48.81 | ★ $12.24 |
| Revenue Growth | 17.88 | ★ 21.13 |
| 52 Week Low | $15.78 | $25.52 |
| 52 Week High | $80.58 | $40.93 |
| Indicator | TTMI | HRMY |
|---|---|---|
| Relative Strength Index (RSI) | 48.17 | 57.18 |
| Support Level | $61.38 | $38.12 |
| Resistance Level | $80.58 | $40.87 |
| Average True Range (ATR) | 4.59 | 1.35 |
| MACD | -1.16 | -0.22 |
| Stochastic Oscillator | 30.00 | 42.28 |
TTM Technologies Inc manufactures technology solutions, including mission systems, radio frequency (RF) components/RF microwave/microelectronic assemblies, quick-turn and technologically printed circuit boards (PCB). The company is based in the United States and derives roughly half of its revenue domestically. It organizes itself into two segments: printed circuit boards and RF&S Components. The printed circuit boards segment, which contributes the majority of revenue, offers a range of printed circuit boards as well as layout design and simulation, and testing services. TTM Technologies' products are used in manufacturing, networking, telecommunications, computing, aerospace, and medical fields.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.